IL1RL1 and hydrops fetalis: Although some circulating biomarkers (soluble suppressor tumorigenicity-2, galectin-3) may offer new opportunities to improve clinical outcomes in HF patients, in most cases, they do not have the predictive value of elevated NT-proBNP levels in patients with symptomatic HF of diverse phenotypes.